These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 211362)

  • 1. The effect of drugs which alter GABA-ergic function on cerebellar guanosine-3',5'-monophosphate content.
    Mailman RB; Mueller RA; Breese GR
    Life Sci; 1978 Aug; 23(6):623-7. PubMed ID: 211362
    [No Abstract]   [Full Text] [Related]  

  • 2. Striato-cerebellar pathway controlling cyclic GMP content in the cerebellum: role of dopamine, GABA and enkephalins.
    Biggio G; Corda MG; Casu M; Gessa GL
    Adv Biochem Psychopharmacol; 1978; 18():227-44. PubMed ID: 206110
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of chronic treatment with neuroleptics on the content of 3',5'-cyclic guanosine monophosphate in cerebellar cortex of rats.
    Biggio G; Corda MG; Casu M; Gessa GL
    Life Sci; 1978 Aug; 23(6):649-52. PubMed ID: 29201
    [No Abstract]   [Full Text] [Related]  

  • 4. Baclofen and cerebellar cyclic GMP levels in mice.
    Gumulka SW; Dinnendahl V; Schönhöfer PS
    Pharmacology; 1979; 19(2):75-81. PubMed ID: 231264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different mechanisms mediating the decrease of cerebellar cGMP elicited by haloperidol and diazepam.
    Biggio G; Costa E; Guidotti A
    Adv Biochem Psychopharmacol; 1976; 15():325-35. PubMed ID: 192052
    [No Abstract]   [Full Text] [Related]  

  • 6. Evidence for an involvement of GABA in the mediation of the cerebellar cGMP decrease and the anticonvulsant action diazepam.
    Mao CC; Guidotti A; Costa E
    Naunyn Schmiedebergs Arch Pharmacol; 1975; 289(4):369-78. PubMed ID: 240134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dopaminergic agonists and antagonists on in vivo cyclic nucleotide content: relation of guanosine 3':5'- monophosphate (cGMP) changes in cerebellum to behavior.
    Breese GR; Mueller RA; Mailman RB
    J Pharmacol Exp Ther; 1979 May; 209(2):262-70. PubMed ID: 35602
    [No Abstract]   [Full Text] [Related]  

  • 8. Changes of rat cerebellar guanosine 3',5'-cyclic phosphate by dopaminergic mechanisms in vivo.
    Burkard WP; Pieri L; Haefely W
    Adv Biochem Psychopharmacol; 1976; 15():315-24. PubMed ID: 192051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central GABA receptor agonists: comparison of muscimol and baclofen.
    Naik SR; Guidotti A; Costa E
    Neuropharmacology; 1976 Aug; 15(8):479-84. PubMed ID: 185540
    [No Abstract]   [Full Text] [Related]  

  • 10. Involvement of glutamate and gamma-aminobutyric acid (GABA)-ergic systems in thyrotropin-releasing hormone-induced rat cerebellar cGMP formation.
    Nakayama T; Hashimoto T; Nagai Y
    Eur J Pharmacol; 1996 Dec; 316(2-3):157-64. PubMed ID: 8982682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of desmethyldiazepam and chlordesmethyldiazepam on 3',5'-cyclic guanosine monophosphate levels in rat cerebellum.
    Govoni S; Fresia P; Spano PF; Trabucchi M
    Psychopharmacology (Berl); 1976 Nov; 50(3):241-4. PubMed ID: 188062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the mechanism of the decrease in cerebellar cyclic GMP content elicited by opiate receptor agonists.
    Biggio G; Guidotti A; Costa E
    Naunyn Schmiedebergs Arch Pharmacol; 1977 Jan; 296(2):117-21. PubMed ID: 189228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethanol-induced depletion of cerebellar guanosine 3',5' -cyclic monophosphate.
    Redos JD; Catravas GN; Hunt WA
    Science; 1976 Jul; 193(4247):58-9. PubMed ID: 180596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologically induced changes in the 3':5'-cyclic guanosine monophosphate content of rat cerebellar cortex: difference between apomorphine, haloperidol and harmaline.
    Biggio G; Costa E; Guidotti A
    J Pharmacol Exp Ther; 1977 Jan; 200(1):207-15. PubMed ID: 13199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dopaminergic agonists and antagonists on cerebellar guanosine-3',5'-monophosphate (cGMP).
    Breese GR; Mailman RB; Ondrusek MG; Harden TK; Mueller RA
    Life Sci; 1978 Aug; 23(5):533-6. PubMed ID: 29192
    [No Abstract]   [Full Text] [Related]  

  • 16. In vivo changes of guanosine 3',5'-cyclic phosphate in rat cerebellum by dopaminergic mechanisms.
    Burkard WP; Pieri L; Haefely W
    J Neurochem; 1976 Jul; 27(1):297-8. PubMed ID: 182922
    [No Abstract]   [Full Text] [Related]  

  • 17. Morphine reduces cerebellar guanosine-3',5'-cyclic monophosphate content and elevates cerebrospinal fluid guanosine-3',5'-cyclic monophosphate content in rhesus monkey.
    Katz JB; Catravas GN; Valases C; Wright SJ
    Life Sci; 1978 Feb; 22(6):467-72. PubMed ID: 203814
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of ethanol, arecoline, atropine and nicotine, alone and in various combinations, on rat cerebellar cyclic guanosine 3',5-monophosphate.
    Dodson RA; Johnson WE
    Neuropharmacology; 1979 Nov; 18(11):871-6. PubMed ID: 233143
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-lasting inhibitory action of caerulein on climbing fiber system in the cerebellum of the rat.
    Kageyama H; Kurosawa A
    Neuropharmacology; 1989 Sep; 28(9):991-5. PubMed ID: 2554189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of some gamma-aminobutyric acid (GABA)-ergic drugs on the dopaminergic control of human growth hormone secretion.
    Koulu M; Lammintausta R; Dahlström S
    J Clin Endocrinol Metab; 1980 Jul; 51(1):124-9. PubMed ID: 6769935
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.